Angiotensin II contributes to myocardial tissue remodeling and interstitial fibrosis through NADPH oxidase-mediated generation of oxidative stress in the progression of heart failure. Recent data have suggested that nebivolol, a third-generation β-blocker, improves diastolic dysfunction by targeting nitric oxide (NO) and metabolic pathways that decrease interstitial fibrosis. We sought to deter...

BACKGROUND The significance of beta-blockers in the treatment of cardiovascular diseases is well established. The effect of vasodilating beta-blockers on endothelial function and prothrombotic state has not been investigated. METHODS The study comprised 550 consecutive patients with uncomplicated essential hypertension. They were treated with celiprolol, carvedilol or nebivolol monotherapy (1...

BACKGROUND We aimed to assess the effects of irbesartan and nebivolol on the left atrium (LA) volume and deformation in the patients with mild-moderate hypertension. PATIENTS AND METHODS The study comprised of 160 patients (mean age: 55.6±9.6 years), who had Stage 1 or 2 hypertension according to the European Society of Cardiology (ESC) and have not been receiving antihypertensive therapy. Th...

Beta blockers play an important role in the treatment of many cardiovascular diseases. Despite their beneficial effect, the significant difference in their pharmacological properties will influence their metabolic effect. The aim of the present study is to compare the metabolic effect of 4 different beta blockers; two nonvasodilator beta blockers (a non-selective beta blocker, propanolol and ca...

The present study describes the development and validation of sensitive, novel Ultra Performance Liquid Chromatographic technique to simultaneously evaluate Nebivolol and Valsartan in commercial pharmaceutical capsule formulation. The technique was performed utilizing thermo C18 (4.6 mm×50 mm, 1.9 μm) column having a mobile phase comprising of 10 mM ammonium dihydrogen phosphate pH adjusted to ...

BACKGROUND More than 50% of the patients with heart failure have normal ejection fraction (HFNEF). Iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy and cardiopulmonary exercise test (CPET) are prognostic markers in HFNEF. Nebivolol is a beta-blocker with vasodilating properties. OBJECTIVES To evaluate the impact of nebivolol therapy on CPET and123I-MIBG scintigraphic parameters in ...

Objective: Heart failure is one of the most important disease which threats population’s health. Its prevalance increases both in our country and world years. Nebivolol a molecule proved its efficacy treatment heart failure. The aim this study was to evaluate changes echocardiographic parameters such as tissue doppler imaging myocardial performance index (MPI) after 6 months nebivolol patients ...

OBJECTIVES The aim of this study was to investigate if the new generation beta-blockers are as effective as irbesartan, which is an angiotensin receptor blocker (ARB), on left ventricular hypertrophy (LVH). PATIENTS AND METHODS The study included 85 patients (average age: 56.6±9.6 year) with stage 1 and 2 hypertension, who previously didn't receive an antihypertensive treatment, but diagnosed...

Nebivolol, a cardioselective β-blocker undergoes extensive metabolism in the liver after its oral administration resulting in low bioavailability. Oral administration of nebivolol also causes gastrointestinal disturbances characterised by stomach ache. To overcome these short comings, mucoadhesive buccal films of nebivolol were prepared using different concentrations of hydroxypropyl methylcell...